Special Issue "RNA Viruses and Cancer"
A special issue of Biology (ISSN 2079-7737).
Deadline for manuscript submissions: closed (31 January 2013)
Prof. Dr. Santanu Bose
Department of Microbiology and Immunology, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
Phone: +1 210 567 1019
Fax: +1 210 567 6612
Interests: respiratory RNA virus infections; oncolytic RNA viruses; oncolytic RNA virus based anti-cancer therapeutics
RNA viruses are important class of human pathogens that causes an array of human diseases. RNA viruses can also act as oncoviruses to promote cancer development (oncogenesis). For example, retrovirus like Human T lymphotrophic virus type 1 (HTLV-I) has been associated to T-cell leukemia, while hepatitis C virus (HCV) has been linked to development of liver cancer. Several RNA viruses also possess anti-cancer property. Known as oncolytic viruses, these viruses specifically “kills” cancer cells, but not normal cells. RNA viruses that possess oncolytic activity are vesicular stomatitis virus (VSV), measles virus, respiratory syncytial virus (RSV), Newcastle disease virus (NDV), mumps virus, reovirus, coxsackie virus, poliovirus. In the last decade major stride has been made in understanding the mechanism of oncogenesis by HTLV-I and HCV. These have led to development of treatment regimen to combat virus-associated cancers. Similarly, research with oncolytic viruses has illustrated the possible usage of these natural or genetically engineered “anti-cancer” viruses to treat various cancers and solid tumors either alone or in combination with other non-virus cancer agents (radiation, chemotherapy etc). This has culminated in major progress for development of safe and efficacious oncolytic viruses that can specifically target cancer cells (and tumors). This special issue will publish original research papers and review articles on RNA oncovirues (HTLV-I and HCV) and oncolytic viruses that possess RNA genome.
Prof. Dr. Santanu Bose
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biology is an international peer-reviewed Open Access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 300 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
- RNA oncoviruses
- RNA oncolytic viruses
- Hepatitis C virus (HCV)
- Human T lymphotrophic virus type 1 (HTLV-I)
Biology 2013, 2(3), 936-975; doi:10.3390/biology2030936
Received: 6 May 2013; in revised form: 11 June 2013 / Accepted: 18 June 2013 / Published: 2 July 2013| Cited by 2 | PDF Full-text (1011 KB) | HTML Full-text | XML Full-text
Biology 2013, 2(2), 587-602; doi:10.3390/biology2020587
Received: 4 February 2013; in revised form: 28 February 2013 / Accepted: 5 March 2013 / Published: 28 March 2013| Cited by 1 | PDF Full-text (174 KB) | HTML Full-text | XML Full-text
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Type of Paper: Review
Title: Hepatitis C Virus and Hepatocellular Carcinoma
Authors: Tatsuo Kanda 1,*, Osamu Yokosuka 1 and Masao Omata 2,3
Affiliations: 1 Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba (260-8670), Japan; E-Mails: firstname.lastname@example.org (T.K.); email@example.com (O.Y.)
2 Yamanashi Hospitals (Central and Kita) Organization, 1-1-1 Fujimi, Koufu-shi, Yamanashi (400-8506), Japan; E-Mail: firstname.lastname@example.org (M.O.)
3 University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo (113-8655), Japan
Abstract: Hepatitis C virus (HCV), a hepatotropic virus, is a single stranded-positive RNA virus with ~9600 nt. in length, which belongs to the Flaviviridae family. HCV infection causes acute hepatitis, chronic hepatitis, cirrhosis and hepatocellular carcinoma (HCC). It has been reported that HCV-coding proteins interact host-cell factors, which are involved in cell cycle regulation, transcriptional regulation, cell proliferation and apoptosis. Severe inflammation and advanced liver fibrosis in the background of the liver is also associated with the incidence of HCV-related HCC. In this review, we discuss the mechanism of hepatocarcinogenesis in HCV-related liver diseases.
Type of Paper: Review
Title: Reovirus Clinical Trials: Past, Present and Future Perspectives
Authors: Chandini Thirukkumaran, Matt Coffey and Don Morris
Affiliation: Department of Oncology, Tom baker Cancer Centre, University of Calgary, 1331 – 29 Street NW, Calgary, AB, Canada T2N 4N2; E-Mail: email@example.com
Abstract: Reovirus, an ubiquitous double stranded RNA virus has been shown to target cancer but not normal cells under in vitro, in vivo, and ex vivo conditions. These findings have provided pre-clinical data for the ongoing advanced stage clinical trials. To realize the full potential of this virus in a clinical setting, optimizing the host/tumour/virus microenvironment is imperative. Paradoxically, immune clearance of the virus presents a limitation in reovirus treatment of patients whereas harnessing the immune system towards an anti-tumour and immune surveillance of the cancer represents a pivotal advantage in patient treatment. This review presents a timely overview of the clinical trials that have been conduced to date: from primates to phase III trials, lessons learnt from these trials and future clinical trials that are planned. Strategies that will be developed to overcome hurdles faced in the clinic that may lead to attainment of the full clinical potential of this viral therapeutic that has versatile activity against a spectrum of histologies will also be discussed.
Last update: 10 October 2013